Sequence Bio
Discovering the true signals of disease to power life-changing drugs.
90% of drug candidates fail, delaying help for those in need. We’re on a mission to change that. Better drug target discovery powered by the Newfoundland founder effect.
Former Founders
Jeremy Grushcow
Ph.D. in Molecular Genetics and Cell Biology (University of Chicago, 2000); J.D. with Honors (University of Chicago Law School, 2003).
Previously: CBO, Sequence Bio S19 (Raised >$10m; LOIs signed with Sema4, Helix and Biogen); EVP, Strategic Development, Antibe Therapeutics (International partnerships, public company financings and disclosures; preclinical through Phase 1 for a novel pain therapeutic)
Best dog dad ever; 7 out of 10 human dad.
Chris Gardner
